The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Eczema can’t be passed from person to person. This article explores the primary differences between these two skin conditions, including their causes, symptoms, and treatments. Scabies is caused ...

Side effects relating to ozone therapy can vary depending on the type of treatment a person undergoes. People should never inhale ozone. If it enters the mouth, nose, or eyes, it can burn and ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes the sell-off has created an attractive buying opportunity. While ...

Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares quadruple last year.

Close on Skyrizi’s tail was Dupixent, as Sanofi and Regeneron threw ... Obesity-focused Wegovy took sixth place, while diabetes treatment Ozempic landed in 10th, with $31 million and $14.2 ...